PURPOSE: Anti-PD-1 antibodies are widely used for cancer treatment, including in advanced renal cell carcinoma (RCC). However, the therapeutic response varies among patients. This study aimed to predict tumor response to nivolumab anti-PD-1 antibody ...
BMC medical informatics and decision making
Oct 13, 2022
BACKGROUND: Efficient exploration of knowledge for the treatment of recurrent glioblastoma (GBM) is critical for both clinicians and researchers. However, due to the large number of clinical trials and published articles, searching for this knowledge...
Clinical cancer research : an official journal of the American Association for Cancer Research
Mar 20, 2020
PURPOSE: Using standard-of-care CT images obtained from patients with a diagnosis of non-small cell lung cancer (NSCLC), we defined radiomics signatures predicting the sensitivity of tumors to nivolumab, docetaxel, and gefitinib.
Clinical pharmacology and therapeutics
Dec 19, 2019
Lower clearance of immune checkpoint inhibitors is a predictor of improved overall survival (OS) in patients with advanced cancer. We investigated a novel approach using machine learning to identify a baseline composite cytokine signature via clearan...
The Journal of thoracic and cardiovascular surgery
Dec 13, 2018
OBJECTIVE: We conducted a phase I trial of neoadjuvant nivolumab, a monoclonal antibody to the programmed cell death protein 1 checkpoint receptor, in patients with resectable non-small cell lung cancer. We analyzed perioperative outcomes to assess t...
Fumarate hydratase-deficient renal cell carcinoma (FHdRCC) is a rare and aggressive form of kidney cancer that presents significant therapeutic challenges. Due to its rarity, treatment decisions often rely on comprehensive literature reviews to ident...
Gan to kagaku ryoho. Cancer & chemotherapy
Dec 1, 2023
A 25-year-old male received palliative total gastrectomy plus D1 dissection plus Roux-en-Y reconstruction for hemorrhagic gastric cancer with left Virchow lymph node metastasis in 2013. The final diagnosis was Type 2, pT4a(se), pap>tub2 >hepatoid ade...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.